Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy

被引：16

作者：

Brown, Zachary J. ^{[1
]}

Hewitt, D. Brock ^{[1
]}

Pawlik, Timothy M. ^{[1
]}

机构：

[1] Ohio State Univ, Wexner Med Ctr, Dept Surg, Div Surg Oncol, Columbus, OH 43210 USA

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2022年 / 27卷 / 03期

关键词：

review; intrahepatic cholangiocarcinoma; biomarker; targeted therapy; immunotherapy; BILIARY-TRACT CANCER; ISOCITRATE DEHYDROGENASE 1; SERUM CYFRA 21-1; PROGNOSTIC-FACTOR; PHASE-II; CYTOKERATIN-19; FRAGMENT; PYRUVATE-KINASE; EXPRESSION; PROTEIN; MARKERS;

D O I：

10.31083/j.fbl2703085

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer behind hepatocellular carcinoma (HCC) and carries a dismal prognosis. Improved genetic analysis has paved the way for a better understanding of the distinct somatic genomic landscapes of ICC. The use of next generation sequencing has paved the way for more personalized medicine through identifying unique mutations which may prove to be therapeutic targets. The ability to identify biomarkers specific to ICC will assist in establishing a diagnosis, monitoring response to therapy, as well as assist in identifying novel therapies and personalized medicine. Herein, we discuss potential biomarkers for ICC and how these markers can assist in diagnosis, monitor response to therapy, and potentially identify novel interventions for the treatment of ICC.

引用

页数：16

共 154 条

[1] Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [J].

Abou-Alfa, Ghassan K. ;

Macarulla, Teresa ;

Javle, Milind M. ;

Kelley, Robin K. ;

Lubner, Sam J. ;

Adeva, Jorge ;

Cleary, James M. ;

Catenacci, Daniel V. ;

Borad, Mitesh J. ;

Bridgewater, John ;

Harris, William P. ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Whisenant, Jonathan ;

Lowery, Maeve A. ;

Goyal, Lipika ;

Shroff, Rachna T. ;

El-Khoueiry, Anthony B. ;

Fan, Bin ;

Wu, Bin ;

Chamberlain, Christina X. ;

Jiang, Liewen ;

Gliser, Camelia ;

Pandya, Shuchi S. ;

Valle, Juan W. ;

Zhu, Andrew X. .

LANCET ONCOLOGY, 2020, 21 (06) :796-807

[2] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].

Abou-Alfa, Ghassan K. ;

Sahai, Vaibhav ;

Hollebecque, Antoine ;

Vaccaro, Gina ;

Melisi, Davide ;

Al-Rajabi, Raed ;

Paulson, Andrew S. ;

Borad, Mitesh J. ;

Gallinson, David ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Dotan, Efrat ;

Catenacci, Daniel, V ;

Van Cutsem, Eric ;

Ji, Tao ;

Lihou, Christine F. ;

Zhen, Huiling ;

Feliz, Luis ;

Vogel, Arndt .

LANCET ONCOLOGY, 2020, 21 (05) :671-684

[3] Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies [J].

Acher, Alexandra W. ;

Paro, Alessandro ;

Elfadaly, Ahmed ;

Tsilimigras, Diamantis ;

Pawlik, Timothy M. .

CANCERS, 2021, 13 (20)

[4] Molecular pathogenesis of intrahepatic cholangiocarcinoma [J].

Andersen, Jesper B. .

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2015, 22 (02) :101-113

[5] Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors [J].

Andersen, Jesper B. ;

Spee, Bart ;

Blechacz, Boris R. ;

Avital, Itzhak ;

Komuta, Mina ;

Barbour, Andrew ;

Conner, Elizabeth A. ;

Gillen, Matthew C. ;

Roskams, Tania ;

Roberts, Lewis R. ;

Factor, Valentina M. ;

Thorgeirsson, Snorri S. .

GASTROENTEROLOGY, 2012, 142 (04) :1021-U552

[6] Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles [J].

Beal, Eliza W. ;

Cloyd, Jordan M. ;

Pawlik, Timothy M. .

JOURNAL OF CLINICAL MEDICINE, 2021, 10 (01) :1-17

[7] Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma [J].

Beal, Eliza W. ;

Tumin, Dmitry ;

Moris, Dimitrios ;

Zhang, Xu-Feng ;

Chakedis, Jeffery ;

Dilhoff, Mary ;

Schmidt, Carl M. ;

Pawlik, Timothy M. .

HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (04) :270-276

[8] NCCN Guidelines® Insights Hepatobiliary Cancers, Version 1.2017 Featured Updates to the NCCN Guidelines [J].

Benson, Al B., III ;

D'Angelica, Michael I. ;

Abbott, Daniel E. ;

Abrams, Thomas A. ;

Alberts, Steven R. ;

Saenz, Daniel Anaya ;

Are, Chandrakanth ;

Brown, Daniel B. ;

Chang, Daniel T. ;

Covey, Anne M. ;

Hawkins, William ;

Iyer, Renuka ;

Jacob, Rojymon ;

Karachristos, Andrea ;

Kelley, R. Kate ;

Kim, Robin ;

Palta, Manisha ;

Park, James O. ;

Sahai, Vaibhav ;

Schefter, Tracey ;

Schmidt, Carl ;

Sicklick, Jason K. ;

Singh, Gagandeep ;

Sohal, Davendra ;

Stein, Stacey ;

Tian, G. Gary ;

Vauthey, Jean-Nicolas ;

Venook, Alan P. ;

Zhu, Andrew X. ;

Hoffmann, Karin G. ;

Darlow, Susan .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (05) :563-573

[9] Combinatorial strategies for the induction of immunogenic cell death [J].

Bezu, Lucillia ;

Gomes-de-Silva, Ligia C. ;

Dewitte, Heleen ;

Breckpot, Karine ;

Fucikova, Jitka ;

Spisek, Radek ;

Galluzzi, Lorenzo ;

Kepp, Oliver ;

Kroemer, Guido .

FRONTIERS IN IMMUNOLOGY, 2015, 6

[10] Cholangiocarcinoma: Current Knowledge and New Developments [J].

Blechacz, Boris .

GUT AND LIVER, 2017, 11 (01) :13-26

← 1 2 3 4 5 6 7 8 9 10 →